Health Care • Medicinal Chemicals and Botanical Products
$1.37 ▼ -0.02
(-1.44%)
MKT CAP: $79.1M • VOL: 6.8K
52W L $1 52W H $4
ISPR // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-06-30 | FY 2024
FILED 2024-06-30 | FY 2023
FILED 2023-06-30 |
|---|---|---|---|
| Revenue (Total Sales) | $127.5M | $151.9M | $115.6M |
| YoY Revenue Growth % | -16.1% | +31.4% | — |
| Gross Profit | $22.6M | $29.8M | — |
| Gross Margin % | 17.8% | 19.6% | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$37.8M | -$13.9M | -$4.5M |
| Operating Margin % | -29.7% | -9.1% | -3.9% |
| Net Income (GAAP) | -$39.2M | -$14.8M | -$6.0M |
| EBITDA (Normalized) | -$37.0M | -$12.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$7.4M | -$18.3M | -$8.5M |
| Capital Expenditures (CapEx) | $1.1M | $2.0M | — |
| Free Cash Flow (FCF) | -$8.5M | -$20.3M | -$8.5M |
| FCF Margin % | -6.6% | -13.3% | -7.3% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $17.6M | $34.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | -$7.7M | $24.2M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ISPR.